Dr Reddy's Laboratories To Buy IP Rights Of Anti-Coagulant Drug For $17.5M

Australian drug discovery and development company Alchemia entered into a $17.5 million agreement with Dr Reddy’s laboratories for exclusive intellectual property rights for anti-coagulant drug.

The sale is conditional on shareholder approval, as the sale constitutes a disposal of the company's main undertaking as per ASX listing rules, said the statement by Alchemia.

Cipla Pharma Appoints Dr Reddy�s Former Us Generics Head As Global CFO
Umang Vohra as Cipla’s Global Chief Financial and Strategy Officer would bring deep insights about the global generics industry and understanding of value creation.

An anti-coagulant drug, fondaparinux sodium is generic version of Arixtra drug and has been approved by US and Europe for treating deep vein thrombosis and pulmonary embolism, it added.

Alchemia markets Fondaparinux in the US and other markets through partner Dr. Reddy Laboratories, the statement added.

Source-IANS

Rivastigmine Tartrate Capsules Recalled from the US Market by Dr Reddy�s Laboratories
For the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease Rivastigmine Tartrate Capsules are indicated.

Dr Reddy�s Laboratories Launch Tablets For Treatment Of Dementia In The US Market
Memantine hydrochloride tablets in the strengths of 5 mg and 10 mg are launched after getting the approval from the US Food and Drug Administration.

IPCA, Dr Reddy�s Health Products Come Under Canada Govt Scanner
Canadian importers have been asked to quarantine health products made in India due to data integrity concerns.